One of the critical issues in thyroid cancer diagnostic is differentiation between follicular adenoma, follicular carcinoma and the follicular variant of papillary carcinoma, which in some cases is not possible based on histopathological features only. In this paper we performed molecular profiling of thyroid tissue aiming to identify metabolites characteristic for different types of thyroid cancer. FFPE tissue specimens were analysed from 5 different types of thyroid malignancies (follicular, papillary/classical variant, papillary/follicular variant, medullary and anaplastic cancers), benign follicular adenoma and normal thyroid. Extracted metabolites were identified and semi-quantified using the GC/MS approach. There were 28 metabolites identified, whose abundances were significantly different among different types of thyroid tumours, including lipids, carboxylic acids, and saccharides. We concluded, that multicomponent metabolome signature could be used for classification of different subtypes of follicular thyroid lesions. Moreover, potential applicability of the GC/MS-based analysis of FFPE tissue samples in diagnostics of thyroid cancer has been proved.
Introduction
Thyroid tumours represent the most common endocrine malignancy in the general population (DeLellis et al., 2004; Eszlinger and Paschke, 2010) . There are several types of thyroid cancer distinguished on the basis of histopathological features, including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), medullary thyroid carcinoma (MTC), poorly differentiated carcinoma and anaplastic thyroid carcinoma (ATC) (Salabe, 2001) . PTC and FTC are the most frequent thyroid cancers, contributing to more than 70% and about 15% of all cases, respectively. Undifferentiated ATC, representing only 1e2% of thyroid cancers, is the most aggressive thyroid malignancy with the worst prognosis (Oertel, 2004) . MTC (comprising of 3e5% cases), unlike other thyroid carcinomas arising from the follicular cells, is derived from the parafollicular C cells and reveals neuroendocrine features (Hedinger et al., 1998) . Proper classification of thyroid cancer is the primary step in the assessment of prognosis and selection of the treatment. Most patients with thyroid cancer are initially diagnosed based on the fine needle aspiration cytology (FNAC) of thyroid nodules. However, this method has several limitations, especially in refined classification of cancer subtypes (Sakorafas, 2010; Kakudo et al., 2014 ). An important issue in thyroid cancer diagnostic is differentiation between follicular adenoma, follicular carcinoma and the follicular variant of papillary carcinoma. In certain cases papillary carcinomas share some architectonic features with follicular tumours (called the follicular variant of PTC) (Schlumberger, 2007; Ustun et al., 2014) . Moreover, papillary structures of follicular cells are also observed in nodular goiter, cysts, hyperplasic areas of follicular tumors, Graves' disease, thyroiditis (Rosai et al., 1992; Lloyd et al., 2011) . Furthermore, encapsulated follicular variant of papillary carcinoma can be misdiagnosed with benign follicular adenoma (Silver et al., 2011) . The hyalinising trabecular adenoma, a distinctive lesion, may also mimic medullary and papillary carcinoma microscopically (Greco et al., 2009) . Hence, proper distinction of thyroid lesions has important implication for clinical management. However, in some cases cytological and histological pattern are inconclusive and such classification could be problematic (Faquin, 2008) .
The categorization of thyroid cancer subtypes could be currently supported by molecular biomarkers, including markers identified with the use of high-throughput "omics" techniques (Fujarewicz et al., 2007; Xing et al., 2013; Stokowy et al., 2014a Stokowy et al., , 2014b . Metabolomics represent a valuable approach to system biology, which allows the discovery of novel molecular markers of cancer (Stokowy et al., 2014b; Hood et al., 2009; Spratlin et al., 2009) . In recent years several works have shown significant differences in the composition of metabolites present in normal and cancerous thyroid tissues (Yao et al., 2011; Ishikawa et al., 2012; Miccoli et al., 2012; Torregrossa et al., 2012; Deja et al., 2013; Guo et al., 2014a; Wojakowska et al., 2015) . Several metabolic signatures characteristic for major types of thyroid lesions have been registered using different NMR techniques Deja et al., 2013) . Different methods based on mass spectrometry (MS) techniques have been also used in metabolomic studies of thyroid cancer. Imaging mass spectrometry (IMS) has been used to analyse the differential distribution of phospholipids in PTC and non-cancerous thyroid tissue (Ishikawa et al., 2012) . Analysis of thyroid tissue by IMS combined with MS-based profiling of the serum lipidome revealed differences in the composition of choline-containing phospholipids, phosphatidic acids and sphingomyelins between thyroid cancers (PTC and FTC) and benign lesions (Guo et al., 2014a) . Moreover, LC-MS based analysis of the serum lipidome allowed for the detection of lipids, the abundances of which discriminated patients with PTC from healthy controls or patients with non-malignant lesions (Yao et al., 2011 ). However, current metabolomic studies have not delivered methodology and biomarker candidates that could be implemented in clinical diagnostics for differentiation and classification of thyroid cancer subtypes yet.
In the present study, the combination of gas chromatography and mass spectrometry (the GC/MS approach), which is frequently used in metabolomics studies, has been applied to searching for the signature of metabolites specific to different types of thyroid tumours. Formalin-fixed paraffin-embedded (FFPE) tissue specimens have been used, which is the most relevant type of clinical material. The fixation process allows the storage of such material at ambient temperature during long period of time, while paraffin embedding facilitates the preparation of samples for pathological examination, hence FFPE samples constitute a highly valuable source of clinical material for retrospective analysis. However, the requirement for paraffin removal, which can lead to damage or loss of targeted compounds, constitute some limitation in certain molecular studies (Nirmalan et al., 2008; Reimel et al., 2009; Klopfleisch et al., 2011) . Hence, the extraction of small molecules from FFPE material for MS-based metabolomic analyses remains a challenging task. In this work we optimized the procedure for extraction of small metabolites from FFPE thyroid tissue samples and their subsequent profiling using the GS/MS technique, and identified molecules with abundances discriminating between different subtypes of thyroid lesions. The results of this work demonstrate relevance of the GC/MS-based metabolome profiling for retrospective studies of thyroid cancer, and indicate its potential applicability as an ancillary tool in diagnostic of thyroid lesions.
Materials and methods

Clinical material
Tissue samples were collected from Caucasian patients with diagnosed thyroid tumours, who were operated in the period between 2000 and 2014. Tissue samples were selected and histologically described before analysis by an experienced pathologist. Five types of thyroid cancer were analysed: follicular carcinoma (FTC; 7 patients), classical variant of papillary carcinoma (PTC-CV; 4 patients), follicular variant of papillary carcinoma (PTC-FV; 4 patients), medullary carcinoma (MTC; 6 patients) and anaplastic carcinoma (ATC; 6 patients). Additionally, samples of follicular adenoma (FA; 3 patients) and control non-cancerous thyroid (Ctr; 5 patients) were used (addition information on clinical material is given in Supplementary Table A). All tissue specimens were fixed in neutral buffered formalin (4% formaldehyde in phosphate buffer, pH 7.0) immediately after resection, embedded in paraffin and stored in room temperature.
The study was approved by the appropriate Ethics Committee and all participants provided informed consent indicating their conscious and voluntary participation.
Extraction of metabolites from FFPE samples
Samples of thyroid cancers selected for analyses contained at least 90% of tumour cells and no necrotic areas. Two adjacent 10 mm-thick FFPE tissue sections were placed in 1.5 ml tube and mixed with 1 ml of xylene, then centrifuged for 5 min at 13 000 rpm in 4 C. The supernatant was discarded and the deparaffinization treatment was repeated, then the pellet was dried in a desiccator for 2 h. Dried samples were homogenized in 250 ml mixture of MeOH:H 2 O (1:1 v/v), vortexed for 5 min and placed in an ultrasonic bath for 10 min. The resulting mixture was centrifuged for 10 min at 16 000 rpm in 4 C, and then the supernatant was spin-filtered through PVDF 0.22 mm centrifugation units (Millipore) to generate the polar fraction. The pellet was resuspended in 250 ml mixture of Ch 2 Cl 2 :MeOH (3:1 v/v) and processed as described above to generate the non-polar fraction. Both fractions were combined, transferred to a new tube and evaporated in vacuum concentrator. The dried extract was then derivatized with 25 ml of methoxyamine hydrochloride in pyridine (20 mg/ml) at 37 C for 90 min with agitation (950 rpm). The second step of derivatization was performed by adding 40 ml of MSTFA and incubation at 37 C for 30 min with agitation (950 rpm). Samples were subjected to GC/MS analysis directly after derivatization; each sample was prepared in three repetitions.
GC/MS analysis
The GS/MS analysis was performed using Agilent 7890A gas chromatograph (Agilent Technologies) connected to Pegasus 4D GCxGC-TOFMS mass spectrometer (Leco). A DB-5 bonded-phase fused-silica capillary column (30 m length, 0.25 mm inner diameter, 0.25 mm film thickness) (J&W Scientific Co.,USA) was used for separation. The GC oven temperature program was as follows: 2 min at 70 C, raised by 8 C/min to 300 C and held for 16 min at 300 C. The total time of GC analysis was 46.75 min. Helium was used as the carrier gas at a flow rate of 1 ml/min. One microliter of each sample was injected in splitless mode. The initial injector temperature was 20 C for 0.1 min and after that time raised by 600 C/min to 350 C. The septum purge flow rate was 3 ml/min and the purge was turned on after 60 s. The transfer line and ion source temperatures were set to 250 C. In-source fragmentation was performed with 70 eV energy. Mass spectra were recorded in the mass range 35e650 m/z.
Analysis of spectra
Data acquisition, automatic peak detection, mass spectrum deconvolution, retention index calculation and library search were done by Leco ChromaTOF-GC software (v4.51.6.0). To eliminate retention time (Rt) shift and to determine the retention indexes (RI) for each compound, the alkane series mixture (C-10 to C-36) was injected into the GC/MS system. The metabolites were automatically identified by library search (Replib, Mainlib, Fiehn library); the analyte was considered as identified when passed quality threshold: i.e., similarity index (SI) above 700 and matching retention index ± 10. The artifacts (alkanes, column bleed, plasticizers, MSTFA and reagents) were identified using Replib, Mainlib and Fiehn databases, and then excluded from further analyses. To obtain accurate peak areas for the deconvoluted components, unique quantification masses for each component were specified and the samples were reprocessed. The obtained profiles were normalized against the sum of chromatographic peak area (using the TIC approach).
Statistical and chemometric analyses
Ten samples representative for each group of patients (i.e. with outliers detected and removed), with the exception of the FA group with 8 samples, were analysed, to secure a balanced design. Quantitative analysis was performed for metabolites identified in at least 60% of samples in each group; the missing values were imputed using the k-nearest neighbour method with the standardised Euclidean metric. The data were log-transformed, and their normality and homoscedasticity was assessed using the Lilliefors' test and the Bartlett's test, respectively. Differences in abundances of metabolites among analysed groups were tested using the ANOVA or the KruskaleWallis ANOVA tests, depending on the normality and homoscedasticity of each metabolite's distribution across the groups; the p-values were corrected using the BenjaminieHochberg FDR approach in each case. When the corrected ANOVA test indicated differences of signal distribution among groups, the significance of differences between particular groups was estimated pairwise using appropriate post-hoc testing (the Tukey HSD test or the Nemenyi test with the Dunn correction, depending on the normality and homoscedasticity of the data). Principal Component Analysis (PCA) was conducted for data overview and outlier detection. Data normalization was performed using sum of bucket values in the analysis. PCA and PLS were performed without any scaling algorithm. HC was performed to illustrate relationships between different thyroid lesions based on the Euclidean distance method. All multivariate data analyses (PCA, PLS, HC) were performed using the Profile Analysis software (Bruker Daltonics, Bremen, Germany). Metabolomic pathways were identified using the Metabolite Set Enrichment Analysis (MSEA) (available at http://www.msea.ca/MSEA/faces/Home.jsp), which is the metabolomic version of Gene Set Enrichment Analysis (GSEA) approach. A list of selected metabolites was used as an input for the Over Representation Analysis (ORA) algorithm, which was implemented using the hypergeometric test to evaluate over representation of a particular metabolite set; provided were foldenrichment values and one-tailed p-values corrected for multiple testing.
Results and discussion
GC/MS could be used for molecular profiling of FFPE thyroid tissues
We have described the profiling of metabolites present in FFPE thyroid tissue samples using the GC/MS technique. To the best of our knowledge, this is the first GC/MS-based protocol demonstrating successful profiling of metabolites from archive FFPE tissue. This approach allowed for identification and quantification of 81 unique metabolites present in all types of thyroid specimens, which included amino acids, carbohydrates, carboxylic acids, fatty acids and their esters, sugar alcohols and others; the complete list of identified compounds is presented in Supplementary Table B. For the comparison, fresh-frozen thyroid tissues were analysed using the same analytical platform (including the same extraction procedure without deparaffinization step), which revealed that the majority of metabolites detected in the fresh-frozen tissue could be identified also in FFPE material. However, paraffin embedding and subsequent deparaffinization of tissues influenced stability and/or extraction efficiency of some compounds (e.g. amino acids), which might result in their reduced quantities in FFPE tissue extracts (the comparison of relative abundances of metabolites isolated from FFPE and fresh-frozen PTC samples is presented in Supplementary  Table C) . Nevertheless, obtained results demonstrated the possibility of conducting metabolomic studies using FFPE specimens, which has a high importance for retrospective clinical studies. In the present study we searched for small molecules, which levels were different in extracts from different types of thyroid tumours and non-cancerous thyroid tissue. There were 28 metabolites identified (mostly fatty acids, carboxylic acids and saccharides) with levels showing a statistically significant difference in at least one of compared groups (the analysis of variances test corrected pvalue < 0.05). For all such compounds pairwise analyses were performed in the next step to assess differences between particular groups; the complete list of differentiating metabolites is presented in Supplementary Table D. We concluded that GC/MS-based analysis of FFPE thyroid samples could bring the identification of metabolite signatures discriminating normal tissue and different types of thyroid lesions.
Characterization of differences between cancerous and normal thyroid
Samples of all analysed groups were compared using the unsupervised PCA approach to assess overall similarities and differences among groups (Fig. 1) . This analysis revealed some discrimination between control thyroid tissue and all other types of thyroid lesions. All metabolites with significantly changed abundances between control and cancerous thyroid tissue are listed in Table 1 . There were 15 such differentiating metabolites, mostly lipids, including fatty acids and their propyl or glycerol monoesters. Majority of metabolites discriminating normal and cancerous thyroid were generally downregulated in thyroid cancers, while only lactic acid appeared upregulated in cancerous tissue. Nevertheless, components of thyroid metabolome were identified with different abundances between normal thyroid tissue and thyroid lesions.
The cancer metabolome is generally characterized by variable levels of fatty acids and lipids. In our study we observed generally higher levels of fatty acid esters in control thyroid samples when compared to all thyroid lesions (only in case of MTC such differences were not significant). Decreased levels of lipids in PTC, FTC and FA samples in comparison to control thyroid tissue were previously reported in NMR-based studies of fresh-frozen thyroid material Deja et al., 2013) . However, earlier studies using other MS-based techniques reported increased levels of choline-containing phospholipids, sphingomyelins and 3-hydroxybutyric acid in PTC and FTC compared to normal thyroid (Yao et al., 2011; Ishikawa et al., 2012) , indicating that different classes of lipids likely showed different patterns of changes between normal and cancerous thyroid tissue (yet specific results could be affected by an experimental design). Fatty acids are generally synthesized de novo during cancer progression, yet levels of free fatty acids could vary largely with type of cancer (Menendez and Lupu, 2007; Hilvo et al., 2011; Guo et al., 2014a) . For example, we showed here that MTC was characterized by an elevated level of fatty acids and their propyl or glycerol esters when compared to other thyroid lesions (see Supplementary Table B) . Moreover, differences between control thyroid and MTC were less significant, which suggested that lipid metabolism in MTC (derived from parafollicular C cells) and major cellular mass of normal thyroid was relatively similar. It is noteworthy, that the level of lactic acid was higher in all types of thyroid lesions compared to normal tissue. This phenomenon apparently mirrored the Warburg effect, which was characteristic for many different cancer types (Vander Heiden et al., 2009 ).
Metabolomic differences between follicular thyroid lesions
One of the most important issue in the diagnostics of thyroid cancer is the differentiation between follicular adenoma, follicular carcinoma and the follicular variant of papillary carcinoma, which can share some features in histopathological patterns. To estimate the differences between different follicular lesions (i.e., FA, FTC and PTC-FV), as well as the classical variant of papillary carcinoma (PTC-CV), pairwise analyses were performed using PCA, PLS and hierarchical clustering ( Fig. 2A and Supplementary Figure A) . All types of analyses showed a good separation between PTC-CV and PTC-FV, PTC-FV and FTC, PTC-FV and FA. A weaker discrimination was observed between FTC and FA, which might suggest relative metabolic similarities between these two lesions. Moreover, PCA analysis was performed to estimate similarities between three groups of follicular lesions: FA, FTC and PTC-FV (Fig. 2B) . The obtained PCA score plot showed clear separation of PTC-FV from FTC and FA, yet discrimination between FTC and FA was not satisfactory. In most cases the first two PCA components (PC1 and PC2) contributed to the majority of variance among compared groups (see Supplementary Figure B) . Nevertheless, adding an additional component (PC3) slightly improved separation of FTC from FA, indicating existence of metabolic differences between these two thyroid lesions (Supplementary Figure C) .
In the next step a univariate analysis was performed to asses differences of particular metabolites between above-mentioned types of samples. There were 13 metabolites, which abundances were significantly different between compared groups (Table 2 ). An increased level of citric acid and decreased level of gluconic acid was observed in PTC-CV samples when compared to all types of follicular lesions (FA, FTC and PTC-FV); importantly, the difference was statistically significant between both variants of PTC. Moreover, the abundance of succinic acid differentiated PTC-CV from FTC but not from PTC-FV. Furthermore, an increased level of decanoic acid decyl ester discriminated FTC from PTC-FV and FA. On the other hand, abundances of 11 metabolites differentiated FTC and FA, even though unsupervised analyses indicated relative similarity between these two lesions. It is noteworthy that a decreased level of myo-inositol phosphate was characteristic for FA and discriminated this benign lesion from all types of malignant lesions (including PTC-CV, PTC-FV and FTC). Specific metabolic features discriminating different types of follicular thyroid lesion are summarized in Table 3 . Fig. 3 shows abundances of selected metabolites (succinic acid, citric acid, gluconic acid and myo-inositol phosphate) that differentiated types of thyroid lesions. We concluded that components of thyroid metabolome could be identified with levels discriminating different types of follicular lesions, as well as malignant lesions from benign one.
The distinction between different types of follicular thyroid lesions has an important implication for clinical management. Recent studies have indicated potential applicability of genomic and proteomic biomarkers in differentiation between FA, FTC and PTC-FV (Jarzab et al., 2005; Brown et al., 2006; Eszlinger et al., 2007) . However, there has been no attempt made towards the identification of metabolomic biomarkers for differential classification of follicular thyroid lesions yet. Our study revealed several metabolites that could be used for discrimination between follicular adenoma, follicular carcinoma as well as follicular and classical variant of papillary carcinoma, which included citric, succinic and gluconic acids, as well as mio-inositol phosphate. Citric and succinic acids play important roles in TCA (tricarboxylic acid) cycle, the dysregulation of which is associated with changes in energy requirements. In normal cells glucose is used for production of NADH and ATP through the TCA cycle and oxidative phosphorylation, while cancer cells evade the TCA cycle and use aerobic glycolysis to produce energy (Warburg effect) (Vander Heiden et al., 2009 ). Therefore, differences in levels of citric and succinic acids could reflect different energy demands between thyroid cancer types. On the other hand, gluconic acid is an intermediate in the pentose phosphate pathway (PPP), essential for the production of NADPH required for synthesis of fatty acids and lipids (Cairns et al., 2011) . The level of myo-inositol phosphate was significantly increased in all types of malignant thyroid tumours, hence it could be considered as a potential biomarker candidate for discriminating between benign follicular adenoma and malignant carcinomas. This compound is a precursor of secondary messengers in intracellular signal transduction cascades involved in regulation of proliferation, differentiation and apoptosis, which processes are clearly associated with cancer development (Boss et al., 2006) . Hence, increased level of myo-inositol phosphate apparently reflected progression of cancerous thyroid lesions.
Metabolic pathways affected in thyroid tumours
We have revealed here that fatty acids (and their esters), carboxylic acids (e.g., citric, succinic and lactic acids) as well as certain sugars and their derivatives (glucose, ribose, L-sorbose, gluconic acid and myo-inositol) comprised major classes of metabolites differentiating cancerous lesions of thyroid. In the next step all 28 differentiating metabolites (listed in the Supplementary Table D) were subjected to the Metabolite Set Enrichment Analysis. Metabolic pathways associated with compounds showing different abundances among types of thyroid tumours and normal thyroid tissue are presented on Fig. 4 . We found that metabolic pathways involved in thyroid carcinogenesis included primarily processes connected with energy production: the TCA cycle, electron transport chain, pentose phosphate pathway, glycolysis, gluconeogenesis, galactose and pyruvate metabolism, etc. Moreover, pathways involved in metabolism of lipids and inositol were over-represented among processes associated with metabolites discriminating different types of thyroid lesions and normal thyroid.
The above results could be somehow expected because the major differences in metabolism of normal and cancer cells are connected with pathways involved in production of energy (Cairns et al., 2011) . Additionally, different energy demand of various cancer types could result in their different metabolic profiles, which was revealed here for different types of thyroid lesion. Another characteristic metabolic feature of cancer cells is an altered metabolism of lipids and fatty acids (Jarzab et al., 2005) . Previous studies showed that changes in the levels of different lipids are strongly correlated with cancer, and that cancer progression is associated with lipogenesis de novo (Glaysher, 2013) . Significant upregulation of monounsaturated phosphatidylcholines (MUPCs) was observed in the breast, lung, and thyroid cancer (Ishikawa et al., 2012; Lee et al., 2012; Ide et al., 2013) . Activated lipogenesis associated with upregulation of fatty acid synthase, choline kinase a and stearoyl-CoA desaturase-1 was reported in six different types of cancer, including thyroid (Guo et al., 2014b) . Moreover, it was shown that lipids associated with inflammation and proliferation processes might have prognostic value in cancer diagnostics (Fernandis and Wenk, 2009 ).
Here we have shown that altered metabolism of fatty acids is among metabolic features discriminating different subtypes of thyroid lesions. The pathway analysis has also revealed significance of inositol metabolism, which play an important role in signalling pathways associated with cancer cells progression (Spratlin et al., 2009; Miccoli et al., 2012) . In summary, metabolic signatures that differentiated normal and cancerous thyroid as well as different types of thyroid lesions corresponded to general features of the cancer cell metabolism.
Conclusions
This study focused on application of the GC/MS-based metabolic profiling of FFPE thyroid tissue in a search for potential biomarker candidates allowing classifying different types of thyroid cancers. To the best of our knowledge, this is the first GC/MSbased study demonstrating successful metabolome profiling from archival FFPE tissues, and the first metabolomics study analysing complete spectrum of cancerous thyroid lesions. We revealed several metabolic signatures discriminating cancerous thyroid from normal tissue (including upregulation of lactic acid, and downregulation of several fatty acids and their esters), as well as malignant thyroid cancers from benign follicular adenoma (including upregulation of myo-inositol phosphate, succinic acid, and certain fatty acids and their ester). Furthermore, metabolome components were identified that discriminated classical variant of papillary carcinoma from follicular thyroid lesions (downregulation of gluconic acid and upregulation of citric acid), and differentiating follicular carcinoma from follicular variant of papillary carcinoma (decanoic acid ester). Hence, the GC/MSbased metabolome profiling of FFPE thyroid specimens could be potentially used as an auxiliary diagnostic tool to support classification of thyroid cancers. 
